Shamburg News · 8-K filed Oct 9, 2026, 1:11 PM EDT

Profound Medical Enters Co-Education Agreement with Telix Pharmaceuticals

PROF · Profound Medical Corp.

  • Material agreement
  • Reg FD disclosure
  • Materiality: low

On October 9, 2026, Profound Medical Corp. announced it entered into a co-education agreement with Telix Pharmaceuticals Limited. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET imaging and Profound's TULSA-PRO platform. The press release was furnished as Exhibit 99.1 under Regulation FD and no financial terms were disclosed.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001171843-26-006559.

Written from the filing by Shamburg Markets. Figures are as reported by the company.